Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Idioma
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Zhonghua Yan Ke Za Zhi ; 46(12): 1079-83, 2010 Dec.
Artigo em Zh | MEDLINE | ID: mdl-21211220

RESUMO

OBJECTIVE: To investigate changes of plasma endothelin-1 (ET-1) concentration in photodynamic induced rat anterior ischemic optic neuropathy model (rAION) and evaluate the effects of compound anisodine hydrobromide (CA). METHODS: Eighty-five Sprague-Dawley (SD) male rats were randomly divided into a blank control group of 10 rats and a model group of 75 rats. rAION model was established in the model group by photodynamic induction. The model group was divided into a rAION simple group of 25 rats, a CA intervention group of 25 rats, and a normal saline (NS) control group of 25 rats. Beginning from the day that the rAION model was established, temporal subcutaneous injections (once daily for 3 days) of CA and NS were performed in the CA and the NS groups, respectively. The plasma ET-1 concentrations were detected by radioimmunoassay and analyzed at 1, 3, 5, 7 and 14 days. RESULTS: The means plasma ET-1 concentration of rAION simple group is (114.9±17.6) ng/L, higher than that of the control group (69.4±9.1) ng/L (t=14.92, P<0.01). In the rAION model group, the plasma ET-1 concentrations 1 to 5 days after the model was established were higher than that of 7 to 14 days. During observational periods, on the 1st, 5th, 7th and 14th day, there was no significant difference between the CA and NS groups (t=0.58, 2.07, 0.81 and 0.93, P>0.05), but on the 3rd day the level of plasma ET-1 concentration in the CA group was significantly lower than that of the NS group (t=4.72, P<0.05). CONCLUSIONS: Increase of plasma ET-1 concentrations may play an important role in the pathogenesis of photodynamic induced rAION model. CA can decrease the plasma ET-1 concentrations in rAION rats.


Assuntos
Endotelina-1/sangue , Neuropatia Óptica Isquêmica/sangue , Neuropatia Óptica Isquêmica/tratamento farmacológico , Fotoquimioterapia/efeitos adversos , Derivados da Escopolamina/farmacologia , Animais , Modelos Animais de Doenças , Masculino , Neuropatia Óptica Isquêmica/patologia , Ratos , Ratos Sprague-Dawley , Alcaloides de Solanáceas/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA